CompletedNot Applicable

Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

Taiwan61 participantsStarted 2022-06-01

Plain-language summary

This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anticholinergics or β3-agonist medication for at least 1 month. Exclusion Criteria: * Neurological conditions or spinal cord injury, which could affect urologic function * Advanced pelvic organ prolapse (pelvic organ prolapse quantification system stage II or above) * Active urinary tract infection * Contraindications to taking anticholinergic and β3-agonist medications

What they're measuring

Short form of Urinary Distress Inventory (UDI-6)

Timeframe: Assess before treatment and 12 weeks after treatment

Short form of Incontinence Impact Questionnaire (IIQ-7)

Timeframe: Assess before treatment and 12 weeks after treatment

Overactive Bladder Symptom Score (OABSS)

Timeframe: Assess before treatment and 12 weeks after treatment

Trial details

NCT IDNCT07337252

SponsorMackay Memorial Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Overactive Bladder trials